Clinical trial
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
NCT00329303 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00329303 |
|---|---|
| Title | Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis |
| Official title | Follow-up of Study C87040: Multicentre, Double-blind Study to Describe the Efficacy and Safety of Re-treatment With CDP870 (Certolizumab Pegol) Subcutaneous at 2 Different Dose Regimens (400 mg Initial Dose at Week 0 With 200 mg Every 2 Weeks Thereafter and 400 mg Every 2 Weeks) or Placebo for 12… |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Certolizumab Pegol (Cimzia®) |
| Enrollment | 71 |
| Start date | Apr 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | May 24, 2006 |
| Last update posted | May 6, 2019 |
| Countries | France, Germany |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: